2023
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review
Bartels C, Jorge A, Feldman C, Zell J, Bermas B, Barber C, Duarte‐García A, Garg S, Haseley L, Jatwani S, Johansson T, Limanni A, Rodgers W, Rovin B, Santiago‐Casas Y, Suter L, Barnado A, Ude J, Aguirre A, Li J, Schmajuk G, Yazdany J. Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review. Arthritis Care & Research 2023, 75: 2295-2305. PMID: 37165898, PMCID: PMC10615706, DOI: 10.1002/acr.25143.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusRheumatology Informatics SystemLupus erythematosusDelphi processAmerican CollegeMultidisciplinary Delphi panelPhenotyping of patientsUS rheumatology practicesUrine protein excretionQuality Improvement ProgramReview of guidelinesSLE expertsGlucocorticoid useHydroxychloroquine useKidney functionProtein excretionGlucocorticoid reductionRheumatology practiceEffectiveness (RISE) registryClinical careKidney monitoringEuropean guidelinesErythematosusValidity testingData review
2021
Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia
Renaldi J, Koumpouras F, Dong X. Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia. Lupus 2021, 30: 1844-1848. PMID: 34353174, DOI: 10.1177/09612033211034562.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusQTc prolongationHCQ useLupus patientsQTc intervalFibromyalgia syndromeDose of hydroxychloroquineLethal ventricular arrhythmiasMild QTc prolongationElectronic medical recordsHydroxychloroquine useLupus erythematosusVentricular arrhythmiasMedical recordsBazett's formulaCardiological conditionsOverall prolongationSudden deathHydroxychloroquineImmunomodulatory propertiesAntidepressantsPatientsDrug useConcurrent useECG monitoring
2020
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform
Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Schultze A, Hulme WJ, Croker R, Walker AJ, Williamson EJ, Bates C, Bacon S, Mehrkar A, Curtis HJ, Evans D, Wing K, Inglesby P, Mathur R, Drysdale H, Wong AYS, McDonald HI, Cockburn J, Forbes H, Parry J, Hester F, Harper S, Smeeth L, Douglas IJ, Dixon WG, Evans SJW, Tomlinson L, Goldacre B. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. The Lancet Rheumatology 2020, 3: e19-e27. PMID: 33349815, PMCID: PMC7745258, DOI: 10.1016/s2665-9913(20)30378-7.Peer-Reviewed Original ResearchCOVID-19 mortalitySystemic lupus erythematosusPopulation-based cohort studyLupus erythematosusRheumatoid arthritisOpenSAFELY platformCohort studyImmunosuppressive drugsRheumatological diseasesSevere acute respiratory syndrome coronavirus 2National primary care dataAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Effectiveness of hydroxychloroquinePre-exposure usePrimary care dataSyndrome coronavirus 2COVID-19 outbreakCumulative COVID-19 mortalityCOVID-19Medical Research CouncilNegative control outcomesCOVID-19 deathsHydroxychloroquine useCox regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply